Obstetrics and GynecologyObstetrics and GynecologyАкушерство и гинекология0300-90922412-5679Bionika Media24927910.18565/aig.2020.11.237-242ArticlesСтатьиResearch ArticleUse of dehydroepiandrosterone in a patient with infertility and androgen deficiencyПрименение дегидро-эпиандростерона у пациентки с бесплодием и андрогенным дефицитомGavisovaAlla A.ГависоваАлла Анатольевна

Ph.D., Senior Researcher of the 1st Gynecology Department

к.м.н., старший научный сотрудник 1-го гинекологического отделения

gavialla@yandex.ruShevtsovaMarina A.ШевцоваМарина Антоновна

clinical resident of the 2nd year of study

клинический ординатор 2-го года обучения

marina_98l995@mail.ruTskhovrebovaLinda T.ЦховребоваЛинда Таймуразовна

clinical resident of the 2nd year of study

клинический ординатор 2-го года обучения

linda.tskhovrebova@mail.ruMikhaylovaNina D.МихайловаНина Дмитриевна

graduate student of the 1st year of study

аспирант 1-го года обучения

mihailnina@mail.ruNikolaevaAnastasiya V.НиколаеваАнастасия Владимировна

Ph.D., chief physician

к.м.н., главный врач

a_nikolaeva@oparina4.ruAcademician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России1512202011NO11 (2020)№11 (2020)23724219022023Copyright ©; 2020, Bionika MediaCopyright ©; 2020, ООО «Бионика Медиа»2020Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/0300-9092/article/view/249279

Background. Diminished ovarian reserve is one of the causes of female infertility and a poor response in ovulation induction. Despite advances in clinical embryological approaches and molecular genetic technologies, there are difficulties achieving pregnancy and the birth of a baby with the genetic material from a woman herself with diminished ovarian reserve. Case report. The paper describes a clinical case of the birth of a healthy baby in a patient with diminished ovarian reserve, infertility, and developing premature ovarian failure, who was prescribed dehydroepiandrosterone (DHEA) therapy. Conclusion. The presented clinical case cannot fully demonstrate DHEA treatment success in women with a sharply diminished ovarian reserve. Such situations occur sporadically without DHEA. In the author’s opinion, long-term (9-month) use of DHEA and careful monitoring of the ovaries and hormones are necessary to control treatment efficiency.

Актуальность. Сниженный овариальный резерв является одной из причин женского бесплодия и бедного ответа при индукции овуляции. Несмотря на развитие клинико-эмбриологических подходов и молекулярно-генетических технологий, существуют трудности для достижения беременности и рождения ребенка с генетическим материалом самой женщины при сниженном овариальном резерве. Описание. В представленном клиническом наблюдении описан случай рождения здорового ребенка у пациентки со сниженным овариальным резервом, бесплодием, формирующейся преждевременной недостаточностью яичников, которой была назначена терапия дегидроэпиандростероном (ДГЭА). Заключение. Представленное клиническое наблюдение не может в полной мере демонстрировать успех терапии ДГЭА у женщин с резко сниженным овариальным резервом. Подобные ситуации спорадически встречаются без ДГЭА. По нашему мнению, необходимы длительный прием ДГЭА (9 месяцев) и тщательный мониторинг состояния яичников и гормонов для контроля эффективности лечения.

androgen deficiencyandrogen therapyinfertilityfolliculogenesisdehydroepiandrosteronedehydroepiandrosterone sulfateandrostenedioneандрогенный дефициттерапия андрогенамибесплодиефолликулогенездегидроэпиандростерондегидроэпиандростерон-сульфатандростендионFerraretti A.P., La Marca A., Fauser B.C.J.M., Tarlatzis B., Nargund G., Gianaroli L. ESHRE working group on poor ovarian response definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum. Reprod. 2011; 26(7): 1616-24. https:// dx.doi.org/10.1093/humrep/der092.Goverde A.J., McDonnell J., Schats R., Vermeiden J.P.W., Homburg R., Lambalk C.B. Ovarian response to standard gonadotrophin stimulation for IVF is decreased not only in older but also in younger women in couples with idiopathic and male subfertility. Hum. Reprod. 2005; 20(6): 1573-7. https:// dx.doi.org/10.1093/humrep/deh827.Bosdou J.K., Venetis C.A., Kolibianakis E.M., Toulis K.A., Goulis D.G., Zepiridis L. et al. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum. Reprod. Update. 2012; 18(2): 127-45. https://dx.doi.org/10.1093/humupd/ dmr051.Kyrou D., Kolibianakis E.M., Venetis C.A., Papanikolaou E.G., Bontis J., Tarlatzis B.C. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil. Steril. 2009; 91(3): 749-66. https://dx.doi.org/10.1016/j.fertnstert.2007.12.077.Крстич Е.В., Краснопольская К.В., Кабанова Д.И. Новые подходы к повышению эффективности ЭКО у женщин старшего репродуктивного возраста. Акушерство и гинекология. 2010; 2: 48-53. [Krstich E.V., Krasnopolskaya K.V., Kabanova D.I. New approaches to improving the effectiveness of IVF in older women of reproductive age. Obstetrics and gynecology. 2010; 2: 48-53. (in Russian)].Gleicher N., Barad D.H. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 2011; 9: 67. https://dx.doi.org/10.1186/1477-7827-9-67.Doan H.T., Quan L.H., Nguyen T.T. The effectiveness of transdermal testosterone Gel 1% (Androgel) for poor responders undergoing in vitro fertilization. Gynecol. Endocrinol. 2017; 33(12): 977-9. https://dx.doi.org/10.1080/095135 90.2017.1332586.Horie K., Takakura K., Fujiwara H., Suginami H., Liao S., Mori T. Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Hum. Reprod. 1992; 7(2): 184-90. https:// dx.doi.org/10.1093/oxfordjournals.humrep.a137614.Garcia-Velasco J.A., Moreno L., Pacheco A., Guillen A., Duque L., Requena A. et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil. Steril. 2005; 84(1): 82-7. https://dx.doi.org/10.1016/j. fertnstert.2005.01.117.Nielsen M.E., Rasmussen I.A., Kristensen S.G., Christensen S.T., Mollgard K., Andersen E.W. et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol. Hum. Reprod. 2011; 17(1): 63-70. https:// dx.doi.org/10.1093/molehr/gaq073.Fouany M.R., Sharara FI. Is there a role for DHEA supplementation in women with diminished ovarian reserve? J. Assist. Reprod. Genet. 2013; 30(9): 1239-44. https://dx.doi.org/10.1007/s10815-013-0018-x.Nagels H.E., Rishworth J.R., Siristatidis C.S., Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst. Rev. 2015; (11): CD009749. https:// dx.doi.org/10.1002/14651858.CD009749.pub2.Siristatidis C., Lykakis A., Chrelias C. Proficiency in oocyte retrieval: plausible steps before perfection. Fertil. Steril. 2011; 96(5): e161; author reply e162. https://dx.doi.org/10.1016/j.fertnstert.2011.08.030.Zhang Y., Zhang C., Shu J., Guo J., Chang H.M., Leung P.C.K. et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum. Reprod. Update. 2020; 26(2): 247-63. https://dx.doi.org/10.1093/humupd/dmz046.Genazzani A.D., Stomati M., Strucchi C., Puccetti S., Luisi S., Genazzani A.R. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertil. Steril. 2001; 76(2): 241-8. https://dx.doi.org/10.1016/s0015-0282(01)01902-1.Artini P.G., Simi G., Ruggiero M., Pinelli S., Di Berardino O.M., Pap ini F et al. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol. Endocrinol. 2012; 28(9): 669-73. https:// dx.doi.org/ 10.3109/09513590.2012.705386.Nguyen T.V, McCracken J.T., Ducharme S., Cropp B.F, Botteron K.N., EvansA.C. et al. Interactive effects of dehydroepiandrosterone and testosterone on cortical thickness during early brain development. J. Neurosci. 2013; 33(26): 10840-8. https://dx.doi.org/10.1523/JNEUROSCI.5747-12.2013.Kara M., Aydin T., Aran T., Turktekin N., Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 173: 63-5. https:// dx.doi.org/10.1016/j.ejogrb.2013.11.008.Moawad A.R., Fisher P., Zhu J., Choi I., Polgar Z., Dinnyes A. et al. In vitro fertilization of ovine oocytes vitrified by solid surface vitrification at germinal vesicle stage. Cryobiology. 2012; 65(2): 139-44. https://dx.doi.org/10.1016/j. cryobiol.2012.04.008.Tartagni M., De Pergola G., Damiani G.R., Pellegrino A., Baldini D., Tartagni M.V. et al. Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program. Minerva Ginecol. 2015; 67(1): 7-12.Tartagni M., Cicinelli M.V., Baldini D., Tartagni M.V., Alrasheed H., DeSalvia M.A. et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reprod. Biol. Endocrinol. 2015; 13: 18. https://dx.doi.org/10.1186/s12958-015-0014-3.Wiser A., Gonen O., Ghetler Y., Shavit T., Berkovitz A., Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 2010; 25(10): 2496-500. https://dx.doi.org/10.1093/humrep/ deq220.Yeung T.W.Y., Li R.H.W., Lee V.C.Y., Ho PC., Ng E.H.Y. A randomized doubleblinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2013; 98(1): 380-8. https://dx.doi.org/10.1210/ jc.2012-3071.Yeung T.W.Y., Chai J., Li R.H.W., Lee V.C.Y., Ho P.C., Ng E.H.Y. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil. Steril. 2014; 102(1): 108-15. e1. https://dx.doi.org/10.1016/ j.fertnstert.2014.03.044.Zhang H.H., Xu P.Y., Wu J., Zou ЖЖ, Xu X.M., Cao X.Y. et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J. Ovarian Res. 2014; 7: 93. https://dx.doi.org/10.1186/ s13048-014-0093-3.Kotb M.M., Hass an A.M., AwadAllah A.M. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 200: 11-5. https://dx.doi.org/ 10.1016/j.ejogrb.2016.02.009.